Assessment of minimal clinically important improvement by using Oral Health Impact Profile-14 in Behçet's disease

Clinical and Experimental Rheumatology

Volumn 27, Issue 2 SUPPL.53, 2009, Pages

  Hayran, Osman ^a   Mumcu, Gonca ^b   Inanc, Nevsun ^b   Ergun, Tulin ^b   Direskeneli, Haner ^b  

^a YEDITEPE UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Beh et's disease; Improvement; MCII; OHIP 14; Oral ulcer

Indexed keywords

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL CLINICALLY IMPORTANT IMPROVEMENT; MOUTH ULCER; ORAL HEALTH IMPACT PROFILE 14; PATIENT GLOBAL IMPRESSION OF CHANGE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; BEHCET SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; ORAL ULCER; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70350165970     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. KRAUSE I, WEINBERGER A: Behçet's disease. Curr Opin Rheumatol 2008; 20: 82-87
2. MUMCU G: Behçet disease: Dentist's overview. Clin Exp Rheumatol (Suppl. 50) 2008; 26: S121-125.
3. DIRESKENELI H: Behçet's Disease: Infectious etiology, new auto-antigens and HLA-B51. Ann Rheum Dis 2001; 60: 996-1002.
4. MUMCU G, INANC N, YAVUZ S, DIRESKENELI H: The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease - Review. Clin Exp Rheumatol 2007; 25 (Suppl. 45): S27-33.
5. MUMCU G, ERGUN T, INANC N et al.: Oral health is impaired in Behçet's disease and associate with disease severity. Rheumatology 2004; 43: 1028-1033
6. KARACAYLI U, MUMCU G, SIMSEK I et al.: The close association between dental and periodontal treatments and oral ulcer course in Behcet's disease: A prospective clinical study. J Oral Pathol Med 2009; 38: 410-415
7. MUMCU G, HAYRAN O, OZALP DO et al.: The assessment of oral health related quality of life by factor analysis in patients wih Behçet disease and recurrent apthous stomatitis. J Oral Pathol Med 2007; 36: 147-152
8. MUMCU G, INANC N, ERGUN T et al.: Oral health related quality of life is affected by disease activity in Behçet's disease. Oral Diseases 2006; 12: 145-151
9. MUMCU G, NIAZI S, STEWART J et al.: Oral Health and related quality of life status in patients from UK And Turkey: A Comparative Study In Behçet's disease. J Oral Pathol Med 2009; 38: 406-409
10. SLADE D: Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol 1997; 25: 284-90.
11. MCGRATH C, HEGARTY AM, HODGSON TA, PORTER SR: Patient-centered outcome measures for oral mucosal disease are sensitive to treatment. Int J Oral Maxillofac Surg 2003; 32: 334-336
12. MUMCU G, ERGUN T, ELBIR Y et al.: Clinical and immunological effects of azithromycin in Behcet's disease. J Oral Pathol Med 2005; 34: 13-16 (Pubitemid 40142924)
13. CALGUNERI M, ERTENLI I, KIRAZ S, ERMAN M, CELIK I: Effect of prophylactic benzathine penicilline on mucocutaneous sysmptoms of Behçet's disease. Dermatology 1996; 192: 125-128 (Pubitemid 26072443)
14. HATEMI G, SILMAN A, BANG D et al.: EULAR recommendation for the management of Behçet's disease. Ann Rheum Dis 2008; 67: 1656-1667
15. REVICKI D, HAYS RD, CELLA D, SLOAN J: Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61: 102-109
16. JAESCHKE R, SINGER J, GUYATT GH: Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415
17. KVIEN TK, HEIBERG T, HAGEN KB: Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS):what do these concepts mean? Ann Rheum Dis 2007; 66 (Suppl. III): iii40-iii41.
18. INTERNATIONAL STUDY GROUP FOR BEHCET'S DISEASE: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-1080
19. SALAFFI F, STANCATI A, SILVESTRI CA, CIAPETTI A, GRASSI W: Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004; 8: 283-291
20. TUBACH F, RAVAUD P, BARAN G et al.: Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis:the minimal clinically important improvement. Ann Rheum Dis 2005; 64: 29-33.
21. TUBACH F, RAVAUD P, BEATON D et al.: Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol 2007; 57: 133-139
22. ARPINELLI F, BAMFI F: The FDA guidance for industry on PROs: the point of view of a pharmaceutical company. Health Qual Life Outcomes 2006; 4: 85.
23. REVICKI DA, CELLA D, HAYS RD, SLOAN JA, LENDERKING WR, AARONSON NK: Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006; 27: 70.
24. ALLEN PF: Assessment of oral health related quality of life. Health Qual Life Outcomes 2003; 1: 40.
25. NAITO M, YUASA H, NOMURA Y, NAKAYAMA T, HAMAJIMA N, HANADA N: Oral health status and health-related quality of life: a systematic review. J Oral Sci 2006; 48: 1-7.
26. REVICKI DA, ERICKSON PA, SLOAN JA, DUECK A, GUESS H, SANTANELLO NC; MAYO/FDA PATIENT-REPORTED OUTCOMES CONSENSUS MEETING GROUP. Interpreting and reporting results based on patient-reported outcomes. Value Health 2007;10 (Suppl. 2): S116-24.
27. TURNER D, SCHÜNEMANN HJ, GRIFFITH LE et al.: Using the entire cohort in the receiver operating characteristic analysis maximizes precision of the minimal important difference. J Clin Epidemiol 2009; 62: 374-379
28. SCHUNEMAN HJ, GUYATT GH: Commentary-goodbye M(C)ID! Hello MID, where do you come from? Health Serv Res 2005; 40: 593-597
29. COTEUR G, FEAGAN B, KEININGER DL, KOSINSKI M: Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. Aliment Pharmacol Ther 2009; 29: 1032-1041
30. SHIKIAR R, HARDING G, LEAHY M, LENNOX RD: Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes 2005; 3: 36.
31. ALLEN FP, O'SULLIVAN M, LOCKER D: Determining the minimally important difference for the Oral Health Impact Profile-20. Eur J Oral Sci 2009; 117: 129-134
32. JOHM MT, REIBMANN DR, SZENTPETERY A, STEELE J: Ann approach to define clinical significance in Prosthodontics. J Prosthodont 2009 Apr 3 (Epub).